Src-family kinase inhibitors block early steps of caveolin-1-enhanced lung metastasis by melanoma cells.
Animals
Caveolin 1
/ genetics
Cell Line, Tumor
Cell Movement
/ drug effects
Cell Survival
/ drug effects
Dasatinib
/ pharmacology
Female
Lung Neoplasms
/ drug therapy
Male
Melanoma, Experimental
/ metabolism
Mice
Mice, Inbred C57BL
Neuropeptides
/ metabolism
Phosphorylation
/ drug effects
Protein Kinase Inhibitors
/ pharmacology
Pyrimidines
/ pharmacology
Skin Neoplasms
/ metabolism
Transfection
Tyrosine
/ metabolism
rac1 GTP-Binding Protein
/ metabolism
src-Family Kinases
/ antagonists & inhibitors
Melanoma
Metastasis
Migration
Phospho-caveolin-1
Src-family kinase inhibitors
Journal
Biochemical pharmacology
ISSN: 1873-2968
Titre abrégé: Biochem Pharmacol
Pays: England
ID NLM: 0101032
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
17
01
2020
accepted:
26
03
2020
pubmed:
3
4
2020
medline:
15
12
2020
entrez:
3
4
2020
Statut:
ppublish
Résumé
In advanced stages of cancer disease, caveolin-1 (CAV1) expression increases and correlates with increased migratory and invasive capacity of the respective tumor cells. Previous findings from our laboratory revealed that specific ECM-integrin interactions and tyrosine-14 phosphorylation of CAV1 are required for CAV1-enhanced melanoma cell migration, invasion and metastasis in vivo. In this context, CAV1 phosphorylation on tyrosine-14 mediated by non-receptor Src-family tyrosine kinases seems to be important; however, the effect of Src-family kinase inhibitors on CAV1-enhanced metastasis in vivo has not been studied. Here, we evaluated the effect of CAV1 and c-Abl overexpression, as well as the use of the Src-family kinase inhibitors, PP2 and dasatinib (more specific for Src/Abl) in lung metastasis of B16F10 melanoma cells. Overexpression of CAV1 and c-Abl enhanced CAV1 phosphorylation and the metastatic potential of the B16F10 murine melanoma cells. Alternatively, treatment with PP2 or dasatinib for 2 h reduced CAV1 tyrosine-14 phosphorylation and levels recovered fully within 12 h of removing the inhibitors. Nonetheless, pre-treatment of cells with these inhibitors for 2 h sufficed to prevent migration, invasion and trans-endothelial migration in vitro. Importantly, the transient decrease in CAV1 phosphorylation by these kinase inhibitors prevented early steps of CAV1-enhanced lung metastasis by B16F10 melanoma cells injected into the tail vein of mice. In conclusion, this study underscores the relevance of CAV1 tyrosine-14 phosphorylation by Src-family kinases during the first steps of the metastatic sequence promoted by CAV1. These findings open up potential options for treatment of metastatic tumors in patients in which Src-family kinase activation and CAV1 overexpression favor dissemination of cancer cells to secondary sites.
Identifiants
pubmed: 32240650
pii: S0006-2952(20)30169-6
doi: 10.1016/j.bcp.2020.113941
pii:
doi:
Substances chimiques
AG 1879
0
Cav1 protein, mouse
0
Caveolin 1
0
Neuropeptides
0
Protein Kinase Inhibitors
0
Pyrimidines
0
Rac1 protein, mouse
0
Tyrosine
42HK56048U
src-Family Kinases
EC 2.7.10.2
rac1 GTP-Binding Protein
EC 3.6.5.2
Dasatinib
RBZ1571X5H
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
113941Informations de copyright
Copyright © 2020. Published by Elsevier Inc.